168 related articles for article (PubMed ID: 19301151)
21. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
Bayliss J; Mukherjee P; Lu C; Jain SU; Chung C; Martinez D; Sabari B; Margol AS; Panwalkar P; Parolia A; Pekmezci M; McEachin RC; Cieslik M; Tamrazi B; Garcia BA; La Rocca G; Santi M; Lewis PW; Hawkins C; Melnick A; David Allis C; Thompson CB; Chinnaiyan AM; Judkins AR; Venneti S
Sci Transl Med; 2016 Nov; 8(366):366ra161. PubMed ID: 27881822
[TBL] [Abstract][Full Text] [Related]
22. Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients.
Shuangshoti S; Rushing EJ; Mena H; Olsen C; Sandberg GD
Cancer; 2005 Jun; 103(12):2598-605. PubMed ID: 15861411
[TBL] [Abstract][Full Text] [Related]
23. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
[TBL] [Abstract][Full Text] [Related]
24. DNA ploidy and nuclear morphometry in adult intracranial ependymomas.
Onguru O; Ulutin C; Celasun B; Gunhan O
Clin Neuropathol; 2003; 22(6):266-72. PubMed ID: 14672504
[TBL] [Abstract][Full Text] [Related]
25. Expression of cyclo-oxygenase-2 in ependymal tumors.
Roma AA; Prayson RA
Neuropathology; 2006 Oct; 26(5):422-8. PubMed ID: 17080719
[TBL] [Abstract][Full Text] [Related]
26. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome.
Preusser M; Wolfsberger S; Czech T; Slavc I; Budka H; Hainfellner JA
Am J Clin Pathol; 2005 Oct; 124(4):543-9. PubMed ID: 16146813
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic results of eight patients with intracranial ependymomas].
Sasajima T; Takahashi M; Kinouchi H; Suzuki A; Mizoi K
No To Shinkei; 2003 Mar; 55(3):233-40. PubMed ID: 12728504
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in intracranial ependymomas in children.
Figarella-Branger D; Civatte M; Bouvier-Labit C; Gouvernet J; Gambarelli D; Gentet JC; Lena G; Choux M; Pellissier JF
J Neurosurg; 2000 Oct; 93(4):605-13. PubMed ID: 11014538
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
Witt H; Gramatzki D; Hentschel B; Pajtler KW; Felsberg J; Schackert G; Löffler M; Capper D; Sahm F; Sill M; von Deimling A; Kool M; Herrlinger U; Westphal M; Pietsch T; Reifenberger G; Pfister SM; Tonn JC; Weller M;
Neuro Oncol; 2018 Nov; 20(12):1616-1624. PubMed ID: 30053291
[TBL] [Abstract][Full Text] [Related]
30. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
31. Implications of prognostic markers in brain tumors.
Grzybicki DM; Moore SA
Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718
[TBL] [Abstract][Full Text] [Related]
32. Supratentorial extraventricular ependymomas: A retrospective study focused on long-term outcomes and prognostic factors.
Wang M; Zhang R; Liu X; Li D; Qiu C; Zhao P; Zuo Y; Zhang P; Wang J; Sun H
Clin Neurol Neurosurg; 2018 Feb; 165():1-6. PubMed ID: 29253745
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review.
Zawrocki A; Iżycka-Świeszewska E; Papierz W; Liberski PP; Zakrzewski K; Biernat W
Folia Neuropathol; 2011; 49(2):94-102. PubMed ID: 21845537
[TBL] [Abstract][Full Text] [Related]
34. Current and evolving knowledge of prognostic factors for pediatric ependymomas.
Andreiuolo F; Ferreira C; Puget S; Grill J
Future Oncol; 2013 Feb; 9(2):183-91. PubMed ID: 23414469
[TBL] [Abstract][Full Text] [Related]
35. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
Prayson RA
Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
[TBL] [Abstract][Full Text] [Related]
36. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma.
Ho DM; Hsu CY; Wong TT; Chiang H
J Neurooncol; 2001 Aug; 54(1):77-85. PubMed ID: 11763426
[TBL] [Abstract][Full Text] [Related]
37. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases.
de Andrade FG; Marie SK; Uno M; Matushita H; Taricco MA; Teixeira MJ; Rosemberg S; Oba-Shinjo SM
Neuropathology; 2015 Aug; 35(4):312-23. PubMed ID: 25946121
[TBL] [Abstract][Full Text] [Related]
39. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
Prayson RA
Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
